610 completed, 235 recruiting, 189 terminated, 181 unknown. 1464 Phase 2, 424 Phase 1, 30 Phase 3.
Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-11-02 |
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma SYS6055 - Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | 384 | 2026-12-15 | 2026-10-29 |
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma Glofitamab, Radiotherapy, Obinutuzumab - Relapsed /Refractory DLBCL | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 40 | 2026-12-01 | 2026-06-08 |
| Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 55 | 2026-12-01 | 2026-09-10 |
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
Showing 20 of 1464. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (872) · Lymphoma (442) · Lymphoma, Follicular (431) · Burkitt Lymphoma (419) · Lymphoma, Non-Hodgkin (403) · Lymphoma, B-Cell, Marginal Zone (392) · Lymphoma, Mantle-Cell (349) · Leukemia, Lymphocytic, Chronic, B-Cell (328) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (272) · Recurrence (208) · Lymphoma, Large-Cell, Immunoblastic (196) · Hodgkin Disease (178) · Leukemia (162) · Waldenstrom Macroglobulinemia (160)
Hemic and Lymphatic Diseases (1464) · Neoplasms by Histologic Type (1454) · Immune System Diseases (1452) · Immunoproliferative Disorders (1448) · Lymphatic Diseases (1447) · Lymphoproliferative Disorders (1437) · Neoplasms (1416) · Lymphoma, Non-Hodgkin (1061) · Lymphoma (1022) · Hematologic Diseases (530) · Pathological Conditions, Signs and Symptoms (502) · Pathologic Processes (500) · Disease Attributes (484) · Leukemia, Lymphoid (461)
Rituximab (416) · Cyclophosphamide (346) · Vincristine (168) · Prednisone (153) · Doxorubicin (149) · Etoposide (146) · Cytarabine (100) · Lenalidomide (100) · Filgrastim (89) · Peripheral Blood Stem Cell Transplantation (86) · fludarabine phosphate (84) · Methotrexate (79) · Dexamethasone (71) · Radiotherapy (67) · fludarabine (67)
National Cancer Institute (NCI) (79) · M.D. Anderson Cancer Center (57) · Fred Hutchinson Cancer Center (55) · Memorial Sloan Kettering Cancer Center (35) · Masonic Cancer Center, University of Minnesota (21) · Ruijin Hospital (20) · University of Washington (19) · City of Hope Medical Center (18) · The First Affiliated Hospital of Soochow University (17) · Mayo Clinic (16) · Alliance for Clinical Trials in Oncology (15) · Northwestern University (15) · Novartis Pharmaceuticals (15) · Case Comprehensive Cancer Center (14) · Roswell Park Cancer Institute (14)
United States (857) · China (284) · France (120) · Italy (113) · United Kingdom (90) · Spain (87) · Germany (79) · Canada (68) · Australia (66) · South Korea (66) · Belgium (51) · Poland (40) · Netherlands (35) · Austria (34) · Japan (34)
Ajay Gopal (9) · Craig Moskowitz, MD (7) · Elias Jabbour (7) · Brenda Sandmaier (6) · Reem Karmali, MD (6) · Elias Jabbour, MD (5) · Emanuele Zucca, MD (5) · Julie M Vose, MD (5) · Lode J. Swinnen, MD (5)
PMID 34515338, PMID 41671463, PMID 35622074, PMID 40550489, PMID 39319495, PMID 32499241, PMID 34398557, PMID 40802906, PMID 26373676, PMID 27282998, PMID 30125215, PMID 34780125, PMID 38551807, PMID 17242396, PMID 21527516, PMID 23753028, PMID 23834234, PMID 24224624, PMID 24862638, PMID 26755709, PMID 27209293, PMID 29437592, PMID 30501490, PMID 30518502, PMID 30620669, PMID 31196847, PMID 31527168, PMID 32209572, PMID 33496754, PMID 34310745, PMID 34353848, PMID 34432863, PMID 35422096, PMID 36821767, PMID 38775302, PMID 39240498, PMID 40195173, PMID 40472301, PMID 42411504, PMID 42541678, PMID 10673703, PMID 11600602, PMID 12907446, PMID 1403051, PMID 14508361, PMID 14630682, PMID 14739217, PMID 14767498, PMID 15042678, PMID 15107815
P30CA015704 (24), 2023 (20), P30CA033572 (16), P30CA015083 (13), U10CA032102 (12), 2015 (11), 2017 (11), P30CA043703 (11), 2016 (10), 2014 (9), P30CA016672 (9), P30CA036727 (9), 2018 (8), U10CA031946 (8), U10CA180888 (8)